<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="39">
  <stage>Registered</stage>
  <submitdate>19/07/2005</submitdate>
  <approvaldate>22/07/2005</approvaldate>
  <actrnumber>ACTRN12605000030673</actrnumber>
  <trial_identification>
    <studytitle>Does Lowering Homocysteine slow the rate of memory loss in healthy older people?</studytitle>
    <scientifictitle>The Effect of Homocysteine Lowering Vitamins on Cognitive Performance in healthy older people: a Randomised Controlled Trial</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Normal Ageing</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A randomised, double-blind, placebo-controlled trial. Participants &gt;= 65 years of age with total plasma homocysteine concentrations &gt;=13 [micro]mol/L, and normal renal function were randomised to take a single capsule once daily, containing either a placebo (cellulose) or a combination of 1mg L-Mefolinic acid (folate), 0.5 mg cyanocobalamin and 10mg pyridoxol, over 2 years.</interventions>
    <comparator>Placebo (cellulose) </comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine if the rate in slowing of cognitive perfomance associated with normal ageing can be slowed by lowering homocysteine concentrations when measured by a range of tests of cognition</outcome>
      <timepoint>At 1 and 2 years of intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine if the primary outcome measure is influenced by genotype, older age, higher starting homocysteine concentration, mood state.</outcome>
      <timepoint>After 1 and 2 years of intervention.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Total plasma homocysteine concentration &gt;= 13 [micro]mol/L; not taking supplementary folic acid or vitamins B-12 or B-6; no prior stroke; not diabetic; no established dementia; not taking folate inhibiting  medications (antiepileptics, oral hypoglycaemics, treatment for depression); have normal renal function (creatinine clearance &lt;133 [micro]mol/L in men and &lt; 115 [micro]mol/L in women); availble for at least 2 years.</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation to a group made by a statistician in the Dept of Social and Preventive Medicine (outside Dept Human Nutrition). Capsule packaging done in Switzerland (Eprova); code to capsules held in Switzerland, and sealed and in a locked cabinet in Dunedin till completion of the trial.</concealment>
    <sequence>Before randomisation the sample was stratified using the median values of age and homocysteine concentration. Random numbers between 0 and 1 were generated for each person in each of the 4 groups. Those with random numbers below the median in each group were assigned to group B, and the remainder to group A.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>4/09/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>260</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Otago; Otago Research Grant;</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bristol Myers Squibb Mead Johnson Unrestricted Grant</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr R Moser</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Eprova AG</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>CH-8200 Schaffhausen for all capsules</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Axis-Shield, Norway for holotranscobalamin II analysis kits</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Norway</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jennifer McMahon</name>
      <address>Department of Human Nutrition
University of Otago
P.O. Box 56 
Dunedin Otago 9001</address>
      <phone>+64 3 4797959</phone>
      <fax />
      <email>human-nutrition@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jennifer McMahon</name>
      <address>Department of Human Nutrition
University of Otago
P.O. Box 56
Dunedin Otago 9001</address>
      <phone>+64 3 4797959</phone>
      <fax />
      <email>human-nutrition@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>